Alanna Joyce Church, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
High-Throughput Nucleotide Sequencing | 12 | 2024 | 3671 | 1.160 |
Why?
|
Sarcoma | 6 | 2024 | 1806 | 1.060 |
Why?
|
Soft Tissue Neoplasms | 4 | 2022 | 1166 | 0.960 |
Why?
|
Pathology, Molecular | 3 | 2024 | 329 | 0.850 |
Why?
|
Neoplasms | 13 | 2024 | 22389 | 0.830 |
Why?
|
Neoplasms, Neuroepithelial | 1 | 2021 | 43 | 0.750 |
Why?
|
Genetics, Medical | 1 | 2024 | 334 | 0.740 |
Why?
|
Nevus, Epithelioid and Spindle Cell | 1 | 2022 | 67 | 0.730 |
Why?
|
Sarcoma, Clear Cell | 1 | 2021 | 72 | 0.730 |
Why?
|
Tandem Repeat Sequences | 1 | 2021 | 183 | 0.710 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 2 | 2023 | 183 | 0.680 |
Why?
|
Bone Neoplasms | 3 | 2023 | 2565 | 0.670 |
Why?
|
Nevus, Pigmented | 1 | 2022 | 222 | 0.660 |
Why?
|
Fibrosarcoma | 2 | 2020 | 313 | 0.660 |
Why?
|
Myofibroma | 1 | 2019 | 45 | 0.660 |
Why?
|
Fasciitis | 1 | 2019 | 66 | 0.630 |
Why?
|
Oncogene Proteins, Fusion | 5 | 2024 | 1616 | 0.620 |
Why?
|
Osteosarcoma | 2 | 2023 | 911 | 0.610 |
Why?
|
Ribonuclease III | 1 | 2020 | 271 | 0.600 |
Why?
|
Nephroma, Mesoblastic | 1 | 2017 | 25 | 0.590 |
Why?
|
Parotid Neoplasms | 1 | 2019 | 158 | 0.590 |
Why?
|
Resource Allocation | 1 | 2020 | 354 | 0.590 |
Why?
|
Sequence Analysis, RNA | 5 | 2021 | 2041 | 0.580 |
Why?
|
DEAD-box RNA Helicases | 1 | 2020 | 385 | 0.560 |
Why?
|
Scalp | 1 | 2019 | 391 | 0.550 |
Why?
|
Specimen Handling | 2 | 2021 | 708 | 0.530 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2019 | 465 | 0.530 |
Why?
|
Proto-Oncogene Proteins | 4 | 2022 | 4528 | 0.500 |
Why?
|
Skull | 1 | 2019 | 830 | 0.490 |
Why?
|
Child | 35 | 2024 | 80960 | 0.470 |
Why?
|
Kidney Neoplasms | 3 | 2021 | 4300 | 0.460 |
Why?
|
Microtubule-Associated Proteins | 2 | 2022 | 1074 | 0.440 |
Why?
|
Myofibromatosis | 2 | 2023 | 27 | 0.420 |
Why?
|
Repressor Proteins | 2 | 2021 | 2986 | 0.420 |
Why?
|
Genomics | 10 | 2024 | 5928 | 0.410 |
Why?
|
Serine Endopeptidases | 1 | 2017 | 1027 | 0.400 |
Why?
|
Central Nervous System Neoplasms | 1 | 2020 | 930 | 0.380 |
Why?
|
Gene Fusion | 4 | 2022 | 357 | 0.380 |
Why?
|
Adenomatous Polyposis Coli | 2 | 2023 | 219 | 0.360 |
Why?
|
Hematologic Neoplasms | 1 | 2021 | 1907 | 0.330 |
Why?
|
In Situ Hybridization, Fluorescence | 5 | 2024 | 2525 | 0.310 |
Why?
|
Cell Cycle Proteins | 2 | 2022 | 3450 | 0.280 |
Why?
|
Child, Preschool | 13 | 2024 | 42683 | 0.270 |
Why?
|
Cyclin-Dependent Kinase 4 | 3 | 2024 | 566 | 0.260 |
Why?
|
Skin Neoplasms | 2 | 2023 | 5864 | 0.250 |
Why?
|
Infant | 12 | 2024 | 36556 | 0.250 |
Why?
|
Brain Neoplasms | 3 | 2022 | 9213 | 0.250 |
Why?
|
Dextromethorphan | 1 | 2005 | 37 | 0.240 |
Why?
|
Molecular Targeted Therapy | 4 | 2024 | 2830 | 0.240 |
Why?
|
Dizocilpine Maleate | 1 | 2005 | 171 | 0.240 |
Why?
|
Biomedical Research | 1 | 2020 | 3463 | 0.240 |
Why?
|
Sarcoma, Alveolar Soft Part | 1 | 2024 | 44 | 0.230 |
Why?
|
Protein-Tyrosine Kinases | 3 | 2022 | 2433 | 0.230 |
Why?
|
Hypoxia, Brain | 1 | 2005 | 139 | 0.230 |
Why?
|
Adolescent | 17 | 2024 | 89244 | 0.220 |
Why?
|
Chromosome Aberrations | 2 | 2024 | 1780 | 0.220 |
Why?
|
Lymphangioma | 1 | 2023 | 60 | 0.210 |
Why?
|
Melanoma | 1 | 2022 | 5709 | 0.210 |
Why?
|
Myxoma | 1 | 2023 | 114 | 0.210 |
Why?
|
Humans | 53 | 2024 | 768970 | 0.200 |
Why?
|
Medical Oncology | 2 | 2024 | 2350 | 0.200 |
Why?
|
Fibromatosis, Aggressive | 1 | 2023 | 125 | 0.200 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2021 | 9442 | 0.200 |
Why?
|
Glomus Tumor | 1 | 2022 | 62 | 0.190 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2024 | 325 | 0.190 |
Why?
|
Granuloma, Plasma Cell | 1 | 2022 | 80 | 0.190 |
Why?
|
Neoplasms, Muscle Tissue | 1 | 2021 | 68 | 0.190 |
Why?
|
Receptor, trkA | 1 | 2022 | 159 | 0.180 |
Why?
|
Neocortex | 1 | 2005 | 417 | 0.180 |
Why?
|
Chromosomes | 1 | 2024 | 578 | 0.180 |
Why?
|
Laboratories | 1 | 2024 | 463 | 0.170 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2024 | 2336 | 0.170 |
Why?
|
Hamartoma Syndrome, Multiple | 1 | 2021 | 115 | 0.170 |
Why?
|
Biopsy | 3 | 2020 | 6805 | 0.170 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2020 | 101 | 0.170 |
Why?
|
DNA Copy Number Variations | 2 | 2019 | 2055 | 0.170 |
Why?
|
Codon | 1 | 2021 | 599 | 0.170 |
Why?
|
Tissue Banks | 1 | 2020 | 184 | 0.160 |
Why?
|
Immunophenotyping | 1 | 2024 | 1866 | 0.160 |
Why?
|
Oncogenes | 2 | 2022 | 1236 | 0.160 |
Why?
|
Carcinoma, Medullary | 1 | 2019 | 116 | 0.150 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2020 | 620 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2020 | 228 | 0.150 |
Why?
|
Neuroprotective Agents | 1 | 2005 | 958 | 0.150 |
Why?
|
Carcinoma | 2 | 2021 | 2340 | 0.150 |
Why?
|
Amyloid Precursor Protein Secretases | 1 | 2022 | 614 | 0.150 |
Why?
|
Thyroid Diseases | 1 | 2021 | 385 | 0.140 |
Why?
|
Lymphoma, T-Cell | 1 | 2020 | 308 | 0.140 |
Why?
|
Immunohistochemistry | 3 | 2020 | 11116 | 0.140 |
Why?
|
Young Adult | 7 | 2024 | 60131 | 0.140 |
Why?
|
Thyroid Neoplasms | 2 | 2022 | 2360 | 0.140 |
Why?
|
Spleen | 1 | 2023 | 2294 | 0.140 |
Why?
|
Lymphatic Diseases | 1 | 2018 | 319 | 0.140 |
Why?
|
Liver Neoplasms | 2 | 2024 | 4363 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2017 | 314 | 0.130 |
Why?
|
Mutation | 11 | 2024 | 30266 | 0.130 |
Why?
|
Receptor, IGF Type 1 | 1 | 2018 | 384 | 0.130 |
Why?
|
Necrosis | 1 | 2020 | 1620 | 0.130 |
Why?
|
Piperazines | 2 | 2016 | 2553 | 0.130 |
Why?
|
Male | 24 | 2024 | 365203 | 0.130 |
Why?
|
Neuroblastoma | 1 | 2024 | 1266 | 0.130 |
Why?
|
Information Dissemination | 1 | 2024 | 1141 | 0.130 |
Why?
|
Sexual Development | 1 | 2015 | 39 | 0.130 |
Why?
|
Karyopherins | 1 | 2016 | 134 | 0.130 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2019 | 342 | 0.130 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2018 | 354 | 0.130 |
Why?
|
Exons | 1 | 2021 | 2395 | 0.120 |
Why?
|
GTP Phosphohydrolases | 1 | 2018 | 524 | 0.120 |
Why?
|
Rare Diseases | 2 | 2021 | 631 | 0.120 |
Why?
|
Female | 23 | 2024 | 397515 | 0.120 |
Why?
|
Thyroid Nodule | 1 | 2022 | 767 | 0.120 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2015 | 432 | 0.110 |
Why?
|
Adult | 11 | 2024 | 223851 | 0.110 |
Why?
|
Teratoma | 1 | 2015 | 405 | 0.100 |
Why?
|
Adenoma | 1 | 2023 | 2163 | 0.100 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2019 | 1320 | 0.100 |
Why?
|
Fellowships and Scholarships | 1 | 2021 | 1134 | 0.100 |
Why?
|
Infant, Newborn | 3 | 2024 | 26428 | 0.100 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2016 | 859 | 0.100 |
Why?
|
Cell Proliferation | 2 | 2024 | 10486 | 0.090 |
Why?
|
Recombinant Fusion Proteins | 1 | 2019 | 3744 | 0.090 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2013 | 240 | 0.090 |
Why?
|
Prognosis | 5 | 2023 | 30046 | 0.080 |
Why?
|
Testicular Neoplasms | 1 | 2015 | 808 | 0.080 |
Why?
|
Education, Medical, Graduate | 1 | 2021 | 2422 | 0.080 |
Why?
|
Genetic Testing | 2 | 2021 | 3591 | 0.080 |
Why?
|
Immunotherapy | 1 | 2024 | 4756 | 0.070 |
Why?
|
Curriculum | 1 | 2021 | 3782 | 0.070 |
Why?
|
Glioma | 1 | 2022 | 3532 | 0.070 |
Why?
|
Genetic Predisposition to Disease | 3 | 2024 | 18068 | 0.070 |
Why?
|
Cell Line, Tumor | 5 | 2024 | 17173 | 0.070 |
Why?
|
Proteins | 1 | 2021 | 6011 | 0.070 |
Why?
|
RNA-Binding Proteins | 1 | 2015 | 1891 | 0.070 |
Why?
|
Lymphoma, B-Cell | 1 | 2013 | 945 | 0.070 |
Why?
|
Adenocarcinoma | 2 | 2020 | 6401 | 0.060 |
Why?
|
Cytoskeletal Proteins | 2 | 2022 | 1328 | 0.060 |
Why?
|
Receptors, sigma | 1 | 2005 | 46 | 0.060 |
Why?
|
Neoplasm Transplantation | 2 | 2019 | 2018 | 0.060 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2024 | 3621 | 0.050 |
Why?
|
Scattering, Radiation | 1 | 2005 | 489 | 0.050 |
Why?
|
Nuclear Receptor Coactivator 2 | 1 | 2022 | 40 | 0.050 |
Why?
|
Reproducibility of Results | 1 | 2021 | 20245 | 0.050 |
Why?
|
T-Lymphocytes | 1 | 2020 | 10276 | 0.050 |
Why?
|
Prospective Studies | 3 | 2023 | 54962 | 0.050 |
Why?
|
Adenomatous Polyposis Coli Protein | 1 | 2023 | 182 | 0.050 |
Why?
|
Plasma Cell Granuloma, Pulmonary | 1 | 2021 | 12 | 0.050 |
Why?
|
Membrane Proteins | 1 | 2018 | 7885 | 0.050 |
Why?
|
Mice, Nude | 2 | 2019 | 3631 | 0.050 |
Why?
|
Cortical Spreading Depression | 1 | 2005 | 288 | 0.050 |
Why?
|
Lip | 1 | 2022 | 197 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2024 | 8664 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 3 | 2022 | 5707 | 0.040 |
Why?
|
Oncogene Fusion | 1 | 2020 | 84 | 0.040 |
Why?
|
Cell Cycle | 2 | 2019 | 2937 | 0.040 |
Why?
|
Lung Neoplasms | 2 | 2021 | 13594 | 0.040 |
Why?
|
Receptor, Notch1 | 1 | 2022 | 520 | 0.040 |
Why?
|
RNA Interference | 2 | 2019 | 2835 | 0.040 |
Why?
|
Germ Cells | 1 | 2023 | 644 | 0.040 |
Why?
|
Light | 1 | 2005 | 1355 | 0.040 |
Why?
|
Karyotyping | 1 | 2020 | 1177 | 0.040 |
Why?
|
Calcitonin | 1 | 2019 | 329 | 0.040 |
Why?
|
United States | 2 | 2024 | 73186 | 0.040 |
Why?
|
beta Catenin | 1 | 2023 | 1047 | 0.040 |
Why?
|
Gene Amplification | 1 | 2023 | 1099 | 0.040 |
Why?
|
Receptors, Antigen, T-Cell, gamma-delta | 1 | 2020 | 354 | 0.040 |
Why?
|
Carbazoles | 1 | 2019 | 230 | 0.040 |
Why?
|
Ligands | 1 | 2005 | 3283 | 0.040 |
Why?
|
Neoplasm Metastasis | 2 | 2019 | 4926 | 0.040 |
Why?
|
MicroRNAs | 1 | 2013 | 3811 | 0.040 |
Why?
|
Comparative Genomic Hybridization | 1 | 2017 | 474 | 0.030 |
Why?
|
Sequence Analysis, DNA | 2 | 2017 | 4785 | 0.030 |
Why?
|
PTEN Phosphohydrolase | 1 | 2021 | 1120 | 0.030 |
Why?
|
Retrospective Studies | 5 | 2023 | 81903 | 0.030 |
Why?
|
Gene Rearrangement | 1 | 2020 | 1148 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2022 | 1629 | 0.030 |
Why?
|
Hydrazines | 1 | 2016 | 223 | 0.030 |
Why?
|
Drug Synergism | 1 | 2018 | 1762 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2024 | 2893 | 0.030 |
Why?
|
Neovascularization, Pathologic | 1 | 2024 | 2634 | 0.030 |
Why?
|
Ubiquitin | 1 | 2019 | 843 | 0.030 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2016 | 719 | 0.030 |
Why?
|
Rats, Sprague-Dawley | 1 | 2005 | 8144 | 0.030 |
Why?
|
Orchiectomy | 1 | 2015 | 468 | 0.030 |
Why?
|
Small Molecule Libraries | 1 | 2018 | 742 | 0.030 |
Why?
|
Gene Dosage | 1 | 2017 | 1222 | 0.030 |
Why?
|
Mice | 4 | 2024 | 82072 | 0.030 |
Why?
|
Paraffin Embedding | 1 | 2013 | 306 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2017 | 59739 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2024 | 3608 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2021 | 2167 | 0.020 |
Why?
|
Animals | 5 | 2024 | 169335 | 0.020 |
Why?
|
Base Sequence | 1 | 2022 | 12430 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2022 | 2911 | 0.020 |
Why?
|
Age Factors | 2 | 2020 | 18435 | 0.020 |
Why?
|
Piperidines | 1 | 2019 | 1667 | 0.020 |
Why?
|
Triazoles | 1 | 2016 | 904 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2023 | 3592 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2017 | 21188 | 0.020 |
Why?
|
Databases, Genetic | 1 | 2017 | 1758 | 0.020 |
Why?
|
Doxorubicin | 1 | 2016 | 2234 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2024 | 11262 | 0.020 |
Why?
|
Pediatrics | 1 | 2024 | 3628 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2018 | 6086 | 0.020 |
Why?
|
Rats | 1 | 2005 | 23786 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2017 | 1887 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2024 | 8055 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2016 | 4124 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2024 | 9549 | 0.020 |
Why?
|
Alleles | 1 | 2019 | 6901 | 0.020 |
Why?
|
Ultrasonography | 1 | 2021 | 6002 | 0.020 |
Why?
|
Antineoplastic Agents | 2 | 2020 | 13698 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 11886 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 13021 | 0.020 |
Why?
|
Middle Aged | 2 | 2017 | 223737 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2024 | 65480 | 0.020 |
Why?
|
Aged | 1 | 2017 | 171786 | 0.010 |
Why?
|
Pyridines | 1 | 2016 | 2895 | 0.010 |
Why?
|
Pancreatic Neoplasms | 1 | 2021 | 5443 | 0.010 |
Why?
|
Prevalence | 1 | 2021 | 15879 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2020 | 15471 | 0.010 |
Why?
|
Disease Progression | 1 | 2021 | 13674 | 0.010 |
Why?
|
Kidney | 1 | 2019 | 7058 | 0.010 |
Why?
|
Genetic Variation | 1 | 2018 | 6611 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2018 | 5342 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2020 | 9618 | 0.010 |
Why?
|
Massachusetts | 1 | 2015 | 8894 | 0.010 |
Why?
|
Phenotype | 1 | 2020 | 16731 | 0.010 |
Why?
|
Inflammation | 1 | 2021 | 10868 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 26395 | 0.010 |
Why?
|
Survival Analysis | 1 | 2013 | 10115 | 0.010 |
Why?
|
Gene Expression | 1 | 2013 | 7603 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2020 | 39394 | 0.010 |
Why?
|
Cohort Studies | 1 | 2021 | 41808 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2017 | 16053 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2017 | 6982 | 0.010 |
Why?
|
Signal Transduction | 1 | 2018 | 23653 | 0.010 |
Why?
|
Risk Factors | 1 | 2021 | 74976 | 0.010 |
Why?
|